Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: US FDA Approves Sickle Cell Therapy Endari; Array Submits Binimetinib Again

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.


Related Content

Keeping Track: Thumbs Up For Doptelet And Palynziq, Thumbs Down For Methylene Blue MMX And Meloxicam
User Fee Forecast For May: Approvals Could Sprout In Multiple Divisions
Acorda Decides Tozadenant Isn’t Salvageable, Moves Primary Focus To Inbrija
Acorda's Parkinson's Drug Tozadenant May Not Survive Safety Setback
Sickle Cell Disease Treatment Gets Panel Nod Despite Efficacy Concerns
Array Withdraws Binimetinib's US Filing On Heels Of Late-Cycle Meeting With FDA
Array BioPharma’s Post-Approval Business Strategy Stymied
Deep Breath For Acorda As It Prepares Inhaled Levodopa Filing
Emmaus Sickle Cell NDA Facing FDA Concerns About Clinical Meaningfulness
Delayed Reaction: BioMarin Rises On Pegvaliase Data


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts